Wright S, Dalal G, Vass C, Georgsson S, Payne K. How do women want to receive information about non-invasive prenatal testing? Evidence from a discrete choice experiment. Prenat Diagn. 2022 Oct;42(11):1377-89. doi: 10.1002/pd.6243
Buchanan J, Hill M, Vass CM, Hammond J, Riedijk S, Klapwijk JE, Harding E, Lou S, Vogel I, Hui L, Ingvoldstad-Malmgren C, Soller MJ, Ormond KE, Choolani M, Zheng Q, Chitty LS, Lewis C. Factors that impact on women's decision-making around prenatal genomic tests: an international discrete choice survey. Prenat Diagn. 2022 Jun;42(7):934-46. doi: 10.1002/pd.6159
Kawai AT, Martinez D, Saltus CW, Vassilev ZP, Soriano-Gabarro M, Kaye JA. Incidence of skeletal-related events in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the US. Prostate Cancer. 2019 Jul 9. doi: 10.1155/2019/5971615
Saltus CW, Vassilev ZP, Zong J, Calingaert B, Andrews EB, Soriano-Gabarro M, Kaye JA. Incidence of second primary malignancies in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the United States. Prostate Cancer. 2019 Feb 11;2019:4387415. doi: 10.1155/2019/4387415
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.